|AHFS/Drugs.com||International Drug Names|
|Intravenous (to induce labor), intra-amniotic (to induce abortion)|
|Biological half-life||3 to 6 hours in amniotic fluid, less than 1 minute in blood plasma|
|Chemical and physical data|
|Molar mass||354.48 g/mol|
|3D model (JSmol)|
|(what is this?)|
In domestic mammals, it is produced by the uterus when stimulated by oxytocin, in the event that there has been no implantation during the luteal phase. It acts on the corpus luteum to cause luteolysis, forming a corpus albicans and stopping the production of progesterone. Action of PGF2α is dependent on the number of receptors on the corpus luteum membrane.
Mechanism of action
PGF2α acts by binding to the prostaglandin F2α receptor.
In 2012 a concise and highly stereoselective total synthesis of PGF2α was described. The synthesis requires only seven steps, a huge improvement on the original 17-steps synthesis of Corey and Cheng, and uses 2,5-dimethoxytetrahydrofuran as a starting reagent, with S-proline as an asymmetric catalyst.
The following medications are analogues of prostaglandin F2α:
- Sharma, I.; Dhaliwal, L.; Saha, S.; Sangwan, S.; Dhawan, V. (2010). "Role of 8-iso-prostaglandin F2alpha and 25-hydroxycholesterol in the pathophysiology of endometriosis". Fertility and Sterility. 94 (1): 63–70. PMID 19324352. doi:10.1016/j.fertnstert.2009.01.141.
- Coulthard, G.; Erb, W.; Aggarwal, V. K. (2012). "Stereocontrolled organocatalytic synthesis of prostaglandin PGF2α in seven steps". Nature. 489 (7415): 278–281. PMID 22895192. doi:10.1038/nature11411.
- Corey, E.J.; Cheng, X.M. (1995). The Logic of Chemical Synthesis. Wiley.